BNET Industries
boston scientific corp. - All News and Analysis
Boston Scientific Corp. Q3 2008 Earnings Conference Call Transcript
Question-and-Answer Session[Operator Instructions]. And our first question is from the line of Bob Hopkins with Banc of America. Please go ahead. Robert Hopkins - Banc of America Hi. Thank you and good morning. Two quick questions, first, a very quick one on guidance, and then one on gross margins....
Earnings Preview: Boston Scientific
Boston Scientific Corporation BSX is scheduled to report Q3 earnings before market open Wednesday, Oct. 22, with a conference call scheduled for 8:00 am ET. Guidance Analysts are expecting a profit of 11c on revenue of $1.97B. The consensus range for EPS is 8c to 12c, with a revenue range...
Healthcare Roundup: Anthem Blue Cross Sued, Hospitals Slow Expansions, GM Cuts Healthcare, and More
Anthem Blue Cross sued for rescission-settlement efforts -- Los AngelesĀ City Attorney Rocky Delgadillo sued the health-insurance company, a unit of WellPoint, charging that it illegally sought to reach settlements with policyholders by offering them $1,000 in exchange for dropping all legal claims. Anthem and several other health plans recently...
Abbott, Boston Scientific: Rising Stent Stars
Mike Huckman submits: Veteran medical device analyst Mike Weinstein at JPMorgan is out with a pretty remarkable research note about the fast-changing market for drug-coated stents. Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes...
Paulson & Co. Shows New Stakes in BofA and Cheniere Energy, Among Others
Lon Juricic submits: John Paulson's Paulson & Co. released its 13F for the quarter ended June 30, 2008. Paulson is best know for making an estimated $3-$4 billion by betting against the US housing market. Below are his long positions. Many look like merger-arb trades, but there are...
Medical Devices Are Solid Long-Term
Zacks.com submits: One sector that has kept a promising longer-term outlook is medical devices and supplies. We recently met with Zacks senior analyst Christopher Titus, CFA regarding his outlook on the group, and which companies he would recommend. How has earnings season gone so far? Any...
IHI: Medical Devices Make a Momentum Comeback
Don Dion submits: In the last few months of tough stock-market sledding, one of the tried-and-true axioms of investing has come to the forefront: The health care sector is a good place to hide during bear markets. Over the last three months (through Aug. 8), seven funds...
Board and Executive Compensation in S&P 500
Richard Shaw QVM Group submits: Executive compensation and board largess with high paid executives is a hot topic recently. That spurred us to look comprehensively at some factual comparative data on the total cost of boards of directors and top executive teams among the S&P 500 companies (proxy SPY...
Boston Scientific Corp. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOkay, certainly. [Operator Instructions]. Our first question comes from the line of Larry Keusch of Goldman Sachs. Please go ahead. Lawrence Keusch - Goldman Sachs Yeah, hi, good morning. Jim, I guess two questions for you and... on PROMUS and TAXUS for the next quarter. Looks like based...
Saints Capital to Acquire Interests in Fifty-Four Companies From Boston Scientific Corporation
Saints Capital, a leading secondary direct investment firm, today announced that it has signed a definitive agreement to acquire interests in fifty-four companies from Boston Scientific Corporation, (NYSE: BSX), a worldwide developer, manufacturer and marketer of medical devices.
Fitch Revises Boston Scientific's Outlook to Stable; Affirms 'BB+' IDR
CHICAGO -- Fitch Ratings has affirmed the Issuer Default Rating IDR and outstanding debt ratings on Boston Scientific Corp (NYSE: BSX) as follows.
Medtronic Awarded $250 Million Damages in Patent Case against Boston Scientific
Federal jury in Marshall, Texas, finds that Boston Scientific Corporation infringed three patents owned by Medtronic
Boston Scientific's SpyGlass® Direct Visualization System to Be Prominently Featured at Digestive Disease Week®
Results of international, multi-center registry presented at conference
Boston Scientific Announces Program to Analyze Latitude® Patient Monitoring Data
ALTITUDE clinical science initiative will provide insights to ICD and CRT-D device therapy
Boston Scientific Announces Sponsorship of World Diabetes Day Campaign
Company supports efforts of International Diabetes Federation to promote worldwide diabetes care and prevention
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS™ and TAXUS® Express® Stents
NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed two-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety and efficacy of the market-leading TAXUSR Express2TM Paclitaxel-Eluting Coronary Stent System and reinforce the growing body of positive...
Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
COGNISTM CRT-D and TELIGENTM ICD represent entirely new platforms
Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers
NATICK, Mass., May 8 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced U.S. Food and Drug Administration FDA approval of its ALTRUATM family of pacemakers. ALTRUA is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the...
Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
NATICK, Mass., May 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced CE Mark approval and market launch of its ALTRUATM family of pacemakers. ALTRUA is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first...
Bovie Medical Corporation Acquires Technology, Patents and Assets from Boston Scientific for RF Resection Device
NEW GROWTH OPPORTUNITY EMERGES
Sort byClose
View by Content TypeClose
View by Related Tag Close
- stock (39 results)
- Finance (35 results)
- Guidant Corp. (29 results)
- Johnson & Johnson (28 results)
- Investment (25 results)
- FDA (24 results)
- Healthcare (19 results)
- Boston Globe (17 results)
- Nasdaq Stock Market Inc. (15 results)
- New York Stock Exchange (14 results)
- class action (11 results)
- SALES (11 results)
- agreement (11 results)
- company (11 results)
- Patient (10 results)
- Medtronic Inc. (9 results)
- S&P 500 (9 results)
- stock market (9 results)
- blog (9 results)
- acquisition (8 results)
- Bank of America Corp. (8 results)
- Government (8 results)
- Cisco Systems Inc. (7 results)
- Strategy (7 results)
- Medical Device (7 results)
- Duke University (6 results)
- Readers (6 results)
- Apple Inc. (6 results)
- financial (6 results)
- industry (6 results)
- Health Care (6 results)
- board (6 results)
- Software (6 results)
- SEC (5 results)
- clinical trial (5 results)
- Celsion Corp. (5 results)
- Abbott Laboratories Inc. (5 results)
- AT&T Wireless (5 results)
- Fitch (5 results)
- Microsoft Outlook (5 results)
- shareholder (5 results)
- IDE (4 results)
- SECURITY (4 results)
- MARKETING (4 results)
- merger (4 results)
- Benefits (4 results)
- St. Jude Medical Inc. (4 results)
- Motorola Inc. (4 results)
- analyst (3 results)
- Earnings (3 results)

- Revenue (Fiscal Year) $8.3B
- Profit (Fiscal Year) ($495.0M)
- Incorporated: 1979
- CEO: Mr. James R. Tobin
Boston Scientific is a developer, manufacturer and marketer of medical devices that are used in a variety of interventional medical specialties including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology and neuromodulation. Co.'s products are offered for sale mainly by three business groups: Cardiovascular, which includes its interventional cardiology, cardiac rhythm management and cardiovascular divisions; Endosurgery, which includes its oncology, endoscopy and urology/gynecology divisions; and Neuromodulation, which includes its auditory and pain management divisions.
Competitors
Stock Quote
Board of Directors
Mr. Peter M. Nicholas Chairman
Senator Warren B. Rudman
Mr. John E. Abele
Mr. Joel L. Fleishman
Dr. Kristina M. Johnson Ph.D.
Dr. Ernest Mario Ph.D.
Dr. Uwe E. Reinhardt Ph.D.
Mr. James R. Tobin
Ms. Ursula M. Burns
Ms. Nancy-Ann DeParle
Mr. J. Raymond Elliott
Dr. Marye Anne Fox Ph.D.
Mr. Ray J. Groves
Mr. N. J. Nicholas Jr.
Mr. John E. Pepper Jr.
NAICS Code
Surgical and Medical Instrument Manufacturing: 339112
Industry Transcripts by Seeking Alpha
-
AngioDynamics Inc., F2Q09 (Qtr End 11/30/08) Earnings Call Transcript
on Jan 06, 2009about ANGO
-
Centene Corporation 2009 Financial Guidance Call Transcript
on Dec 19, 2008about CNC
-
Bio-Reference Laboratories, Inc. Q4FY08 Earnings Call Transcript
on Dec 18, 2008about BRLI
-
Magellan Health Services, Inc. 2009 Financial Guidance Call Transcript
on Dec 17, 2008about MGLN
-
The Cooper Companies, Inc. F4Q08 (Qtr End 10/31/08) Earnings Call Transcript
on Dec 09, 2008about COO